Lilly's latest retatrutide data put the spotlight on its next test: a head-to-head trial against its own tirzepatide.
Pushback from Germany and France has secured a key win for medtech in Data Act amendment negotiations, but the industry still ...
Much of oncology’s most useful real-world evidence sits in free-text clinical notes. Validated AI and natural language ...
‘Synchronized Swimming’ Must Wait, But FDA And EMA Ready To Collaborate On Botanical Drug Regulation
FDA and EMA say they could start collaboration on herbal and botanical drug regulation with batch-to-batch quality variation ...
GE HealthCare is buying SOFIE Biosciences to take direct control of Flyrcado’s final-mile distribution, as the company bets ...
The FDA's draft guidance on gene-edited therapies describes how multiple product variants can be included in a single BLA ...
HHS, not the FDA, issued the enforcement discretion policy, which is unusual and suggests a split between the department and ...
The US Food and Drug Administration posted warning letters to three medical device manufacturers on Oct. 27, citing ...
B+L reports Lumify OTC eye drop sales growing 38% were a key revenue driver for its 7% overall Q3 growth to $1.38bn in the ...
The Oct. 30 advisory committee meeting will weigh the FDA’s concerns about the “fragility” of Sydnexis’ data for low-dose ...
Alzheimer’s blood testing is moving into primary care clinics faster than clear guidance for how to integrate the tests. Four ...
Tumaini, an adaptive platform trial of vaccine candidates for Bundibugyo ebolavirus, has begun with MSD’s Ervebo, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results